Kawecka-Jaszcz K, Czarnecka D, Mroczek-Czernecka D, Dubiel J P
I Kliniki Kardiologii Instytutu Kardiologii Akademii Medycznej, Krakowie.
Pol Arch Med Wewn. 1994 Jan;91(1):45-50.
The study group included 30 middle-aged patients (mean = 47.0 +/- 0.6 years) with chronic heart failure (NYHA class III and IV) in the course of primary dilated cardiomyopathy and ischemic heart disease. Enalapril in a dose of 5-10 mg/day was added to previous therapy with digitalis and diuretics. The patients were submitted for noninvasive cardiac and biochemical studies initially and at 3 months. Twenty-four patients completed the planned therapy. In 5 patients the drug had been withdrawn due to hypotension, and one patient died on the fourteenth day of observation because of heart failure worsening. After enalapril therapy 18 patients improved in NYHA functional classes. All patients showed left ventricular improvement based upon left ventricular systolic time intervals, 18 patients showed reduced peripheral vascular resistance, and in 9 patients echocardiography revealed a significant improvement of EF, CI and mVCF. Renal function also improved based upon the decrease in urea and uric acid.
研究组包括30例中年患者（平均年龄47.0±0.6岁），患有原发性扩张型心肌病和缺血性心脏病所致的慢性心力衰竭（纽约心脏协会III级和IV级）。在先前使用洋地黄和利尿剂治疗的基础上，加用剂量为5 - 10毫克/天的依那普利。患者最初及3个月时接受了无创心脏和生化检查。24例患者完成了计划治疗。5例患者因低血压停药，1例患者在观察的第14天因心力衰竭恶化死亡。依那普利治疗后，18例患者纽约心脏协会功能分级改善。所有患者基于左心室收缩时间间期显示左心室功能改善，18例患者外周血管阻力降低，9例患者超声心动图显示射血分数、心脏指数和平均周径缩短率显著改善。基于尿素和尿酸的降低，肾功能也有所改善。
